{"component": "definition", "props": {"groups": [{"snippet_links": [{"key": "with-respect-to", "type": "clause", "offset": [7, 22]}, {"key": "under-development", "type": "definition", "offset": [33, 50]}, {"key": "by-bayer", "type": "clause", "offset": [72, 80]}, {"key": "prior-to", "type": "definition", "offset": [88, 96]}, {"key": "time-of-termination", "type": "clause", "offset": [102, 121]}, {"key": "termination-of-this-agreement", "type": "clause", "offset": [220, 249]}], "size": 3, "snippet": "means, with respect to a Product under development or commercialization by Bayer at, or prior to, the time of termination, any Patents or Know-How Controlled by Bayer or any of its Affiliates as of the effective date of termination of this Agreement, [***].", "samples": [{"hash": "lFCJP7YOuE1", "uri": "/contracts/lFCJP7YOuE1#reversion-technology", "label": "Research Collaboration and Option Agreement (Recursion Pharmaceuticals, Inc.)", "score": 35.1601638794, "published": true}, {"hash": "4UOROQ1GFn7", "uri": "/contracts/4UOROQ1GFn7#reversion-technology", "label": "Research Collaboration and Option Agreement (Recursion Pharmaceuticals, Inc.)", "score": 32.2197113037, "published": true}, {"hash": "4TlgK9gTw18", "uri": "/contracts/4TlgK9gTw18#reversion-technology", "label": "Research Collaboration and Option Agreement (Recursion Pharmaceuticals, Inc.)", "score": 32.1676940918, "published": true}], "hash": "6a2a14b70b3e6cd5aa7410bebf16caaa", "id": 1}, {"snippet_links": [{"key": "gne-foreground-ip", "type": "definition", "offset": [10, 27]}, {"key": "joint-ip", "type": "definition", "offset": [29, 37]}, {"key": "improvement-ip", "type": "definition", "offset": [43, 57]}, {"key": "gne-patents", "type": "definition", "offset": [59, 70]}, {"key": "gne-regulatory-information", "type": "definition", "offset": [86, 112]}, {"key": "gne-background-patents", "type": "definition", "offset": [117, 139]}, {"key": "owned-and-controlled", "type": "definition", "offset": [150, 170]}, {"key": "agreement-or", "type": "definition", "offset": [226, 238]}, {"key": "exclusive-license", "type": "definition", "offset": [243, 260]}], "size": 3, "snippet": "means the GNE Foreground IP, Joint IP, GNE Improvement IP, GNE Patents, GNE Know-How, GNE Regulatory Information and GNE Background Patents, that are owned and Controlled by GNE as of the effective date of termination of this Agreement or the Exclusive License, as applicable;", "samples": [{"hash": "cp4GaCBOfP2", "uri": "/contracts/cp4GaCBOfP2#reversion-technology", "label": "License Agreement (Immunocore LTD)", "score": 32.0390129089, "published": true}, {"hash": "1R0lAp6t8v5", "uri": "/contracts/1R0lAp6t8v5#reversion-technology", "label": "Collaboration Agreement (Immunocore LTD)", "score": 31.9733066559, "published": true}, {"hash": "46PWinONpVi", "uri": "https://ir.immunocore.com/static-files/5863f886-ba1b-4e9e-bd15-7104ff1506a1", "label": "Amendment", "score": 14.5249824524, "published": false}], "hash": "f911a5d56683a112a9623fb2f900d66b", "id": 2}, {"snippet_links": [{"key": "research-program-ip", "type": "definition", "offset": [10, 29]}, {"key": "gne-patents", "type": "definition", "offset": [31, 42]}, {"key": "gne-regulatory-information", "type": "definition", "offset": [58, 84]}, {"key": "gne-background-patents", "type": "definition", "offset": [89, 111]}, {"key": "owned-and-controlled", "type": "definition", "offset": [122, 142]}, {"key": "termination-of-this-agreement", "type": "clause", "offset": [178, 207]}], "size": 2, "snippet": "means the Research Program IP, GNE Patents, GNE Know-How, GNE Regulatory Information and GNE Background Patents, that are owned and Controlled by GNE as of the effective date of termination of this Agreement;", "samples": [{"hash": "9ofY50OlhzW", "uri": "/contracts/9ofY50OlhzW#reversion-technology", "label": "Exclusive Option and License Agreement (Yumanity Therapeutics, Inc.)", "score": 31.8104038239, "published": true}, {"hash": "gq27yno7U1F", "uri": "/contracts/gq27yno7U1F#reversion-technology", "label": "Exclusive Option and License Agreement (Yumanity Therapeutics, Inc.)", "score": 31.7529087067, "published": true}], "hash": "b698ef58e0500621329492ebc6c1cb72", "id": 3}, {"snippet_links": [{"key": "with-respect-to", "type": "clause", "offset": [7, 22]}, {"key": "terminated-product", "type": "clause", "offset": [25, 43]}, {"key": "terminated-territory", "type": "definition", "offset": [51, 71]}], "size": 2, "snippet": "means, with respect to a Terminated Product in the Terminated Territory, [**].", "samples": [{"hash": "bZHZ6HDj2wD", "uri": "/contracts/bZHZ6HDj2wD#reversion-technology", "label": "Collaboration and License Agreement (Sage Therapeutics, Inc.)", "score": 34.1252555847, "published": true}, {"hash": "iddK8hpS0Uu", "uri": "/contracts/iddK8hpS0Uu#reversion-technology", "label": "Collaboration and License Agreement (Sage Therapeutics, Inc.)", "score": 32.1485290527, "published": true}], "hash": "03055bba316745f32f2d79a817804a61", "id": 4}, {"snippet_links": [{"key": "notwithstanding-the-foregoing", "type": "clause", "offset": [17, 46]}, {"key": "research-tools", "type": "definition", "offset": [89, 103]}], "size": 2, "snippet": "means any [***]. Notwithstanding the foregoing, \u201cReversion Technology\u201d shall not include Research Tools.", "samples": [{"hash": "3QzRjB9WkWL", "uri": "/contracts/3QzRjB9WkWL#reversion-technology", "label": "License and Collaboration Agreement (Cullinan Oncology, LLC)", "score": 29.96235466, "published": true}, {"hash": "gHZsORYsrO", "uri": "/contracts/gHZsORYsrO#reversion-technology", "label": "License and Collaboration Agreement (Cullinan Oncology, LLC)", "score": 29.8364143372, "published": true}], "hash": "f617845f68b985d74cc86af9850d2437", "id": 5}, {"snippet_links": [{"key": "by-licensee", "type": "clause", "offset": [41, 52]}, {"key": "with-respect-to", "type": "clause", "offset": [94, 109]}, {"key": "relate-to", "type": "definition", "offset": [135, 144]}, {"key": "reversion-product", "type": "definition", "offset": [176, 193]}, {"key": "composition-of-matter", "type": "definition", "offset": [201, 222]}, {"key": "method-of-use", "type": "clause", "offset": [226, 239]}, {"key": "reasonably-necessary", "type": "clause", "offset": [316, 336]}, {"key": "each-case", "type": "definition", "offset": [392, 401]}, {"key": "date-of", "type": "clause", "offset": [559, 566]}, {"key": "termination-of-this-agreement", "type": "clause", "offset": [572, 601]}, {"key": "for-clarity", "type": "clause", "offset": [618, 629]}, {"key": "other-patents", "type": "definition", "offset": [635, 648]}], "size": 2, "snippet": "means any Patents or Know-How Controlled by Licensee or any of its Affiliates that (a) claim (with respect to Patents) or specifically relate to (with respect to Know-How) any Reversion Product or its composition of matter or method of use, (b) are incorporated into any such Reversion Product, or (c) are otherwise reasonably necessary or have been used to Exploit any Reversion Product, in each case, as such Patents or Know-How exist and are incorporated into any such Reversion Product, in each case, as such Patents or Know-How exist as of the effective date of such termination of this Agreement (but including, for clarity, any other Patents that directly claim priority to any such Patents).", "samples": [{"hash": "5J8ffOuy7Kq", "uri": "/contracts/5J8ffOuy7Kq#reversion-technology", "label": "License Agreement (Gemini Therapeutics, Inc. /DE)", "score": 33.892539978, "published": true}, {"hash": "7brwHcaM1lK", "uri": "/contracts/7brwHcaM1lK#reversion-technology", "label": "License Agreement (Gemini Therapeutics, Inc. /DE)", "score": 33.6680374146, "published": true}], "hash": "e422b0dc126a9fbe9e857d2c9fb210c6", "id": 6}, {"snippet_links": [{"key": "section-743", "type": "clause", "offset": [29, 42]}], "size": 2, "snippet": "has the meaning set forth in Section 7.4.3.", "samples": [{"hash": "frnbd2UqWGe", "uri": "/contracts/frnbd2UqWGe#reversion-technology", "label": "Exclusive License Agreement (Denali Therapeutics Inc.)", "score": 28.8658447266, "published": true}, {"hash": "2QsZW7AG7F4", "uri": "/contracts/2QsZW7AG7F4#reversion-technology", "label": "Exclusive License Agreement (Denali Therapeutics Inc.)", "score": 28.8193016052, "published": true}], "hash": "d0bce0bb76dd68ca9ce2a5bdcd726688", "id": 7}, {"snippet_links": [{"key": "termination-of-this-agreement", "type": "clause", "offset": [35, 64]}, {"key": "with-respect-to", "type": "clause", "offset": [69, 84]}, {"key": "reversion-compound", "type": "definition", "offset": [87, 105]}, {"key": "reversion-product", "type": "definition", "offset": [109, 126]}, {"key": "during-the-term", "type": "clause", "offset": [253, 268]}, {"key": "in-connection-with", "type": "clause", "offset": [273, 291]}, {"key": "activities-under-this-agreement", "type": "clause", "offset": [301, 332]}, {"key": "to-the-extent", "type": "clause", "offset": [421, 434]}, {"key": "patent-claims", "type": "clause", "offset": [440, 453]}, {"key": "in-clause", "type": "clause", "offset": [490, 499]}, {"key": "each-case", "type": "definition", "offset": [514, 523]}, {"key": "but-excluding", "type": "clause", "offset": [688, 701]}], "size": 2, "snippet": "means, as of the effective date of termination of this Agreement and with respect to a Reversion Compound or Reversion Product, any (a) Information Controlled by Sionna or any of its Affiliates as of such date that was invented, discovered or developed during the Term and in connection with \u2587\u2587\u2587\u2587\u2587\u2587\u2019s activities under this Agreement and (b) any Patent Controlled by Sionna or any of its Affiliates as of such date solely to the extent such Patent claims or covers any Information described in clause (a) above, in each case (a)-(b), to the extent actually used by Sionna or its Affiliates in the Exploitation of such Reversion Compound or Reversion Product as of the date of termination; but excluding any Information or Patents with respect to any Sionna Compound or any active therapeutic ingredient that is not a Reversion Compound.", "samples": [{"hash": "e6P6cuJ8g73", "uri": "/contracts/e6P6cuJ8g73#reversion-technology", "label": "License Agreement (Sionna Therapeutics, Inc.)", "score": 36.0444908142, "published": true}, {"hash": "7oN7HH5UG0i", "uri": "/contracts/7oN7HH5UG0i#reversion-technology", "label": "License Agreement (Sionna Therapeutics, Inc.)", "score": 35.6967811584, "published": true}], "hash": "5f3d9330b5bf59f8ca7465863e503f85", "id": 8}, {"snippet_links": [{"key": "termination-of-this-agreement", "type": "clause", "offset": [35, 64]}, {"key": "with-respect-to", "type": "clause", "offset": [69, 84]}, {"key": "continuation-product", "type": "definition", "offset": [87, 107]}, {"key": "research-program", "type": "clause", "offset": [136, 152]}, {"key": "pfizer-patent-right", "type": "definition", "offset": [174, 193]}, {"key": "to-the-extent", "type": "clause", "offset": [208, 221]}, {"key": "in-clause", "type": "clause", "offset": [294, 303]}, {"key": "each-case", "type": "definition", "offset": [318, 327]}, {"key": "to-develop", "type": "definition", "offset": [384, 394]}], "size": 2, "snippet": "means, as of the effective date of termination of this Agreement and with respect to a Continuation Product, (a) Pfizer\u2019s rights in any Research Program Know-How and (b) any Pfizer Patent Right if and solely to the extent such Pfizer Patent Right claims any Research Program Know-How described in clause (a) above, in each case of clause (a) and (b) to the extent necessary or useful to Develop, Commercialize or Manufacture such Continuation Product.", "samples": [{"hash": "boFAVcOl38", "uri": "/contracts/boFAVcOl38#reversion-technology", "label": "Research Collaboration and License Agreement (BioNTech SE)", "score": 30.6865158081, "published": true}, {"hash": "81kBKZ1QJ5j", "uri": "/contracts/81kBKZ1QJ5j#reversion-technology", "label": "Research Collaboration and License Agreement (BioNTech SE)", "score": 30.5906906128, "published": true}], "hash": "bfc6fc985eee9e8e7871171a25bdab5a", "id": 9}, {"snippet_links": [{"key": "denali-patents", "type": "definition", "offset": [10, 24]}, {"key": "regulatory-information", "type": "definition", "offset": [50, 72]}, {"key": "denali-background-patents", "type": "definition", "offset": [77, 102]}, {"key": "each-case", "type": "definition", "offset": [107, 116]}, {"key": "owned-and-controlled", "type": "definition", "offset": [130, 150]}, {"key": "termination-of-this-agreement", "type": "clause", "offset": [189, 218]}, {"key": "specifically-directed", "type": "definition", "offset": [232, 253]}, {"key": "genentech-product", "type": "definition", "offset": [264, 281]}, {"key": "certain-information", "type": "clause", "offset": [287, 306]}, {"key": "in-this-agreement", "type": "definition", "offset": [307, 324]}, {"key": "omitted-and-filed-separately-with-the-securities-and-exchange-commission", "type": "clause", "offset": [334, 406]}, {"key": "subject-of", "type": "clause", "offset": [462, 472]}, {"key": "confidential-treatment-request", "type": "definition", "offset": [475, 505]}], "size": 2, "snippet": "means the Denali Patents, Denali Know-How, Denali Regulatory Information and Denali Background Patents, in each case that (a) are owned and Controlled by Denali as of the effective date of termination of this Agreement, and (b) are specifically directed towards a Genentech Product; *** Certain information in this agreement has been omitted and filed separately with the Securities and Exchange Commission. [***] indicates that text has been omitted and is the subject of a confidential treatment request.", "samples": [{"hash": "frnbd2UqWGe", "uri": "/contracts/frnbd2UqWGe#reversion-technology", "label": "Exclusive License Agreement (Denali Therapeutics Inc.)", "score": 28.8658447266, "published": true}, {"hash": "2QsZW7AG7F4", "uri": "/contracts/2QsZW7AG7F4#reversion-technology", "label": "Exclusive License Agreement (Denali Therapeutics Inc.)", "score": 28.8193016052, "published": true}], "hash": "fc9aac65fe703e3bdfd0d508a3c192ad", "id": 10}], "next_curs": "CmESW2oVc35sYXdpbnNpZGVyY29udHJhY3Rzcj0LEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIdcmV2ZXJzaW9uLXRlY2hub2xvZ3kjMDAwMDAwMGEMogECZW4YACAA", "definition": {"title": "Reversion Technology", "size": 32, "snippet": "means, with respect to a Product under development or commercialization by Bayer at, or prior to, the time of termination, any Patents or Know-How Controlled by Bayer or any of its Affiliates as of the effective date of termination of this Agreement, [***].", "id": "reversion-technology", "examples": ["Effective as of the date of expiration of the Wind-down Period, Licensee hereby grants (without any further action required on the part of Licensor) to Licensor, a royalty-free, fully paid, exclusive, worldwide, irrevocable, perpetual license, with the right to grant sublicenses through multiple tiers, under the <strong>Reversion Technology</strong> (including all Improvements), solely to Develop, Manufacture, and Commercialize Licensed Products throughout the world (the \u201cReversion License\u201d).", "In addition, if the <strong>Reversion Technology</strong> includes Third Party Technology, then no later than [***] after the effective date of the termination, Licensee shall notify Licensor in writing (a \u201cThird Party Technology Notice\u201d), including a description of such Third Party Technology and of all Pass-Thru Obligations owing to the applicable Third Party Licensor with respect to such Third Party Technology (as such terms are defined in Section 2.8 above).", "Upon termination of this Agreement by Genentech for Denali\u2019s material breach under Section 7.2.1 or due to Denali\u2019s insolvency or bankruptcy under Section 7.2.2, and in each case after payment of a First Milestone under Section 4.3, Denali shall grant to Genentech an exclusive right of first negotiation for a license under the <strong>Reversion Technology</strong>, (as defined below) (the \u201cRFN\u201d).", "Promptly following the effective date of termination, Sarepta will provide to Arrowhead all Sarepta Arising Know-How that is included in the <strong>Reversion Technology</strong> for the applicable Terminated Products in the Field [***] that are or have been the subject of Development or Commercialization hereunder as of the effective date of termination (in the form such Terminated Products exist as of the effective date of termination).", "Each Sole Developing Party will retain licenses granted under this Section 11.5(a)(iv) under the <strong>Reversion Technology</strong> from the Non-Developing Party as reasonably necessary to Develop, Manufacture and Exploit those respective Products and Research Programs for so long as such Party continues to Develop and Exploit such Products and Research Programs.", "Genentech hereby grants, effective upon such termination, to NewLink an exclusive (even as to Genentech), sublicenseable, worldwide, royalty-bearing, license under the Genentech <strong>Reversion Technology</strong> to research, develop, import, use, make, have made, offer for sale and sell Reversion Compounds and Reversion Products (including as part of a NewLink Combination Therapy) in the Field in the Territory.", "This Section 4.4.4(b)(iii) (Buy-In) shall survive any expiration or termination of this Agreement and, for clarity, no Unilateral Development Data shall be included within the <strong>Reversion Technology</strong> other than in accordance with this Section 4.4.4(b)(iii) (Buy-In).", "In addition, [*****] of the effective date of termination, Pfizer shall provide to Theravance a copy of all Know-How included in the <strong>Reversion Technology</strong>.", "For clarity, any Sobi Technology or other Intellectual Property resulting from Sobi\u2019s Unilateral Development Activities shall only be included in the <strong>Reversion Technology</strong> if Apellis opts to obtain rights therefore in accordance with Section 4.4.4(b)(iii) (Buy-In).", "Upon any termination of this Agreement other than by [***], the Parties will negotiate in good faith for a period of [***] days following the effective date of such termination to agree on a commercially reasonable royalty for the Reversion License granted to Kura under Section 13.9(b)(i) with respect to KKC <strong>Reversion Technology</strong> (the \u201cReversion Royalty\u201d) and such other terms and conditions (except as expressly set forth herein) applicable to Kura\u2019s practice of the Reversion License."], "related": [["collaboration-technology", "Collaboration Technology", "Collaboration Technology"], ["information-technology", "Information Technology", "Information Technology"], ["dispersion-technique", "Dispersion technique", "Dispersion technique"], ["information-technologies", "Information Technologies", "Information Technologies"], ["communication-technology", "Communication technology", "Communication technology"]], "related_snippets": [], "updated": "2025-12-01T05:47:12+00:00"}, "json": true, "cursor": ""}}